Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey
PURPOSE: To evaluate the pathological adequacy of morcellated ERBT specimens using a two-round Delphi methodology and to establish expert consensus among leading pathologists worldwide. METHODS: Core pathological parameters relevant for ERBT specimens were predefined, and representative high-quality digital slides of morcellated ERBT specimens were selected. These images were reviewed by an international panel of expert uropathologists with extensive experience in bladder cancer. A two-round Delphi survey was conducted, in which panelists rated the importance of predefined pathological parameters on a 5-point Likert scale. The items on which a consensus was not reached during the first round, were reviewed and rephrased for the second round involving the same responders. Consensus was defined as > 75% agreement among participants. RESULTS: 10 responders took part in the survey. During the initial Delphi round, agreement was achieved on six points, covering aspects such as tumor grading and staging (including lympho-vascular invasion, perineural invasion, detrusor muscle presence, grading adequacy, and histological classification). A broader statement also reached consensus, indicating that morcellation following ERBT provides specimen of appropriate quality. After revising the statements, the second round resulted in consensus on three more items: morcellated specimens allow for precise staging, evaluation of detrusor muscle invasion, and identification of carcinoma in situ. CONCLUSION: Tissue acquired after ERBT through morcellation permits dependable pathological evaluation, encompassing grading, staging, and identification of critical prognostic indicators such as carcinoma in situ, detrusor muscle, lymph vascular and perineural invasion. Morcellation is not perceived to compromise pathological evaluation based on expert consensus.
Authors
- Shay Golan (ORCID: https://orcid.org/0000-0002-9205-5820)
- А. Н. Морозов (ORCID: https://orcid.org/0000-0002-8022-990X)
- Dmitry Enikeev (ORCID: https://orcid.org/0000-0001-7169-2209)
- Yossi Ventura (ORCID: https://orcid.org/0000-0002-4768-1160)
- David Lifshitz
- Ezra Baraban
- Eva Compérat
- Jeremy Yuen-Chun Teoh
- Julia Lerner
- Marcelo Combat Faria Tavares
- Eddie Fridman
- Liang Cheng
- Vineet Gauhar
- Shahrokh Shariat
- Max Yakimov
- Konstantin Lokshin
- Thomas R. W. Herrmann
- Ronald Chan
Institutions
- Al-Ahliyya Amman University (JO)
- Universidade Federal de Minas Gerais (BR)
- Johns Hopkins University (US)
- Tel Aviv University (IL)
- Chinese University of Hong Kong (HK)
- Sechenov University (RU)
- Cornell University (US)
- Stellenbosch University (ZA)
- Brown University (US)
- Sheba Medical Center (IL)
- Johns Hopkins Medicine (US)
- Rabin Medical Center (IL)
- Ng Teng Fong General Hospital (SG)
- East Kent Hospitals University NHS Foundation Trust (GB)
- Medizinische Hochschule Hannover (DE)
- Sorbonne Université (FR)
- Comprehensive Cancer Center Vienna (AT)
- Prince of Wales Hospital (CN)
- Hospital das Clínicas da Universidade Federal de Minas Gerais (BR)
- Institute of Nephro Urology (IN)
- Research Institute of Human Morphology (RU)
- Spital Thurgau (Switzerland) (CH)
- Lev Hasharon Hospital (IL)
- Hôpital Tenon (FR)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- World Journal of Urology
- Published
- 2026-05-08
- DOI
- https://doi.org/10.1007/s00345-026-06451-9
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tel Aviv University